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Summary
Hypoxia inducible factors (HIFs) regulate adaptive re-
sponses to changes in oxygen (O2) tension during
embryogenesis, tissue ischemia, and tumorigenesis.
Because HIF-deficient embryos exhibit a number of
developmental defects, the precise role of HIF in early
vascular morphogenesis has been uncertain. Using
para-aortic splanchnopleural (P-Sp) explant cultures,
we show that deletion of the HIF-b subunit (ARNT) re-
sults in defective hematopoiesis and the inhibition of
both vasculogenesis and angiogenesis. These defects
are rescued upon the addition of wild-type Sca-1+
hematopoietic cells or recombinant VEGF.Arnt2/2 em-
bryos exhibit reduced levels of VEGF protein and
increased numbers of apoptotic hematopoietic cells.
These results suggest that HIF coordinates early en-
dothelial cell emergence and vessel development by
promoting hematopoietic cell survival and paracrine
growth factor production.
Introduction
Early in development, the passive diffusion of oxygen
(O2) and nutrients becomes limiting due to rapid cellular
proliferation in gastrulating embryos. Responses to
decreased O2 levels, or hypoxia, are required for normal
development and patterning of the cardiovascular sys-
tem (Ramirez-Bergeron and Simon, 2001). Blood vessel
development consists of two different processes, ‘‘vas-
culogenesis’’ and ‘‘angiogenesis’’ (Risau, 1997). Vascu-
logenesis begins at 7.5 days post coitum (dpc) in the
embryo with the emergence of precursor cells (heman-
gioblasts and/or angioblasts) that proliferate, migrate,
and differentiate into endothelial cells forming the prim-
itive vascular network. Further maturation occurs via
angiogenesis, which involves remodeling by pruning,
branching, and sprouting of preexisting vessels. Ulti-
mately, additional support cells (pericytes/smooth mus-
cle cells) are recruited, and extracellular matrixes are
deposited (Carmeliet, 2005; Coultas et al., 2005; Jain,
2003). Although the molecular mechanism(s) underlying
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are not entirely clear, we and others have demonstrated
that hypoxia inducible factors (HIFs) are critical tran-
scriptional regulators mediating these events (Ramirez-
Bergeron and Simon, 2001: Maltepe and Simon, 1998).
HIF is a member of the basic helix-loop-helix (bHLH)-
PAS family of transcription factors that regulate diverse
biological processes such as O2 homeostasis, circadian
rhythms, neurogenesis, and toxin metabolism. Under
normoxic conditions (R5% O2), the HIF-a proteins are
hydroxylated and targeted for proteosomal degradation
(Ivan et al., 2001; Jaakkola et al., 2001; Yu et al., 2001).
Under low O2 (<5%), however, the a subunits are stabi-
lized and dimerize with a related bHLH-PAS protein
called HIF-b or ARNT (aryl hydrocarbon receptor nuclear
translocator) (Semenza, 1999). HIF is a master regulator
of O2 homeostasis and induces a network of genes im-
portant for angiogenesis, erythropoiesis, and glucose
metabolism (Giaccia et al., 2004). Many genes involved
in cardiovascular differentiation are directly or indirectly
regulated by HIF, including vascular endothelial growth
factor (VEGF), transforming growth factor b1 (TGF-b1),
erythropoietin (EPO), transferrin, platelet-derived growth
factor b (PDGF-b), basic fibroblast growth factor (bFGF),
and/or their receptors (Semenza, 1998, 1999).
Mice lacking HIF activity develop extensive cardio-
vascular pathologies. HIF-1a is ubiquitously expressed
in all tissues, and Hif-1a2/2 embryos die by 10.5 dpc
with various cardiovascular defects, including inade-
quate vessel formation (Iyer et al., 1998; Kotch et al.,
1999; Ryan et al., 1998). In contrast, HIF-2a expression
is more spatially restricted to endothelial cells, mesen-
chyme of the lung, and neural crest derivatives during
embryogenesis (Ema et al., 1997; Tian et al., 1997). Hif-
2a2/2 mice die by 9.5–13.5 dpc due to vascular disorga-
nization in the yolk sac and embryo (Peng et al., 2000)
or later from cardiorespiratory failure due to decreased
lung surfactant or catecholamine production (Comper-
nolle et al., 2002; Tian et al., 1998). A further demonstra-
tion of unique roles for HIF-1a and HIF-2a is their target
gene specificity: glycolytic genes are regulated exclu-
sively by HIF-1a, while HIF-2a preferentially activates
the stress-responsive gene GADD45B and the stem
cell factor Oct-4 (Covello et al., 2006; Hu et al., 2003;
Wang et al., 2005).
ARNT expression is ubiquitous and Arnt2/2 embryos
also die by 10.5 dpc with similar cardiovascular anoma-
lies to theHif-1a2/2mice (Cowden Dahl et al., 2005; Mal-
tepe et al., 1997). In particular, Arnt2/2 yolk sac hemato-
poietic and angiogenic development is disrupted with
aberrant vascular remodeling (Adelman et al., 1999;
Ramirez-Bergeron and Simon, 2001). Moreover, histo-
logical sections of Arnt2/2 placentas demonstrate that
fetal vessels are unable to invade the labyrinthine layer,
and tetraploid chimeric embryo experiments reveal an
Arnt2/2 cardiac phenotype (Adelman et al., 2000). It re-
mains uncertain, therefore, whether yolk sac, placental,
and/or heart defects are the primary cause of vascular
irregularities in Hif-1a2/2, Hif-2a2/2, and Arnt2/2
embryos.
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Whole-mount PECAM stained wild-type embryo (A–C) and yolk sac (G and H) and Arnt2/2 embryo (D–F) and yolk sac (I and J). The Arnt2/2 em-
bryo lacks proper staining of the cardinal vein ([A and D], black arrowheads), heart ([A and D], white arrows), and pharyngeal pouches as seen in
the Arnt+/+ embryo (A and D). Compared to wild-type, the mutant embryo lacks proper inter- and intrasomitic (black arrows, [C and F]) and pe-
ripheral (arrowheads, [B and E]) PECAM staining. Striking decreased staining is observed in the AGM region of the Arnt2/2 embryo (white dotted
lines, [A and B]). Vascular networks, seen as abnormal branching of the vitelline artery in the yolk sac, are deficient in the Arnt2/2 embryo (white
arrows, [G–J]). Immunohistochemical staining with anti-CD34 of Arnt+/+ (K, M, and O) and Arnt2/2 (L, N, and P) 9.5 dpc embryos. The Arnt2/2
embryo lacks proper EC staining in the dorsal aorta (M and N, open arrows) and endocardium ([O and P], arrows). Enlarged boxed area dem-
onstrates the presence of CD34+ hematopoietic cells in the Arnt2/2 embryo (L). Magnifications: (A) and (D), 1203; (G) and (I), 1503; (B), (C),
(E), (F), (H), and (J), 2003; (K) and (L), 1003; (M)–(P), 3003.Given the distinct expression and function(s) of the
HIF-a subunits, we have focused on theArnt null genetic
model where absence of the b subunit completely elim-
inates all HIF activity during cardiovascular differentia-
tion. In this study, we demonstrate thatArnt2/2 embryos
exhibit greatly reduced blood vessel numbers by 9.5
dpc. Since defects in multiple cardiovascular tissues
confound interpretation of these observations, we
performed ex vivo para-aortic splanchnopleural (P-Sp)
explant assays that support both vascular and hemato-
poietic development (Takakura et al., 1998). Here, devel-
opmentally stage-matched wild-type and mutant em-
bryos can be evaluated independently of deleterious
effects caused by abnormal circulation or placentation.
In this context, the Arnt2/2 P-Sp explants exhibited
abnormal vasculogenesis, angiogenesis, and hemato-
poiesis. We determined that endothelial cell production
and vascular morphogenesis are regulated by paracrine
VEGF supplied by hematopoietic cells that are deficient
in Arnt2/2 embryos. Therefore, vascular anomalies ex-
hibited by Arnt2/2 embryos are downstream of the intra-
embryonic hematopoietic defect.
Results
Disruption of Vascular Development in Arnt2/2
Tissues
We have reported previously that the Arnt2/2 mutation
results in extraembryonic vascular and hematopoietic
defects by 10.5 dpc (Adelman et al., 1999; Maltepe
et al., 1997). Further analysis by immunohistochemical
whole-mount staining for the platelet-endothelial celladhesion molecule-1 (PECAM, CD31) demonstrated
abnormal endothelial organization in both extra- and in-
traembryonic Arnt2/2 tissues (Figure 1). At 9.5 dpc, ex-
tensive endothelial remodeling was defective in Arnt2/2
yolk sacs, which displayed a disorganized network
with a honeycomb-like plexus of similar sized capillaries
(Figures 1G–1J). In the embryo itself, Arnt2/2 vessels
were highly disorganized and exhibited a decrease in
PECAM+ cells throughout (Figures 1A–1F). The lack of
large and small vessels was especially apparent in the
cranial region and the P-Sp tissues of Arnt2/2 embryos.
Although the anterior cardinal veins were present in mu-
tant embryos, their remodeling was defective. Further-
more, the developing heart and at least one of the bran-
chial arches also exhibited decreased PECAM staining.
Similarly, the inter- and intrasomitic vessels branching
from the dorsal aorta were absent (Figures 1D–1F).
To further evaluate Arnt2/2 vessel phenotypes, trans-
verse sections from 9.5 dpc embryos were immuno-
stained for CD34, which is expressed on endothelial
and hematopoietic stem cells. As shown in Figures 1K–
1P, Arnt2/2 embryos were defective in CD34 expression
compared to wild-type embryos. Furthermore, the num-
ber of CD34+ cells outlining the dorsal aorta as well as
the endocardium was significantly diminished (Figures
1N and 1P). Of note, some CD34+ hematopoietic cells
were apparent in the Arnt2/2 embryos serving as a posi-
tive control for staining (Figure 1L). In aggregate, these
results reflect endothelial deficiencies in the absence of
ARNT, suggesting that inadequate hypoxic responses
result in improper vessel formation, remodeling, and
maturation throughout the embryo.
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heterozygous intercrosses collected at 9.5 dpc indi-
cated a normal Mendelian ratio (1:2:1) of wild-type, het-
erozygous, and homozygous mutant embryos, respec-
tively (Table S1). However, further staging of embryos
by enumerating paired somite numbers revealed a dis-
proportionate number of Arnt2/2 embryos (50% com-
pared to the expected 25%) with fewer than 15 somites.
In contrast, only 11% of embryos with over 26 somites
were Arnt2/2 mice. Gross observations revealed addi-
tional defects in Arnt2/2 embryos including pericardial
effusion, reduced numbers and sizes of the pharyngeal
pouches, lack of chorio-allantoic fusion, hemorrhagic
lesions, and failure of neural tube closure in some
mutants. We concluded that many (but not all) Arnt2/2
embryos are developmentally delayed by 9.5 dpc.
ARNT Is Required for Appropriate Vasculogenesis
and Angiogenesis in P-Sp Explants
During development, the embryo resides in a hypoxic
environment (Lee et al., 2001; Ryan et al., 1998), and
HIF activates target genes that support vascular devel-
opment. As described above, many Arnt2/2 embryos
are growth impaired by 9.5 dpc. Because the vascular
defects could be the result of general developmental
delay, we employed an ex vivo approach with the para-
aortic splanchnopleural (P-Sp) explant assay, which ex-
amines blood vessel and hematopoietic development
potential of a 9.5 dpc embryo (Takakura et al., 1998,
2000). The P-Sp mesoderm consisting of the dorsal
aorta, genital ridge/gonad, and pro/mesonephros
(aorta-gonad-mesonephros [AGM]) has been suggested
to be a source of intraembryonic hematopoietic and en-
dothelial progenitors (de Bruijn et al., 2002; Dieterlen-
Lievre et al., 2002; North et al., 2002). P-Sp analyses
can determine if the failed Arnt2/2 vessel maturation is
independent of an embryonic developmental delay or
other confounding factors such as yolk sac, cardiac,
and placental defects, which contribute to circulatory
abnormalities. Therefore, a direct role for HIF in intraem-
bryonic vascular and hematopoietic development might
be revealed by P-Sp explant assays.
We generated P-Sp explants from 9.5 dpcArnt2/2 and
wild-type embryos of similar sizes that were matched for
somite numbers ranging from 20 to 30 each. Impor-
tantly, we only used wild-type and mutant embryos
that were morphologically indistinguishable in these as-
says (Figures 2A and 2B). Explants were cultured on OP9
stromal cells for 14 days, and PECAM stained to evalu-
ate endothelial cell (EC) differentiation (Figures 2C–2F).
In these cultures, PECAM+ ECs initially form sheet-like
structures (‘‘vascular beds’’) emulating vasculogenesis,
followed by migration, sprouting, and network formation
of PECAM+ cells in a ring around the explant (‘‘vascular
networks’’) representing angiogenesis (Takakura et al.,
1998). Explants from Arnt+/+ embryos with 20–30 somite
pairs generated visible vascular beds by day 7 that were
further remodeled into networks by day 12 of culture
(Figures 2C and 2D). In direct contrast, few if any vascu-
lar beds or networks were detected in Arnt2/2 P-Sp ex-
plants (Figures 2E and 2F). Although rare, when vascular
beds were observed in Arnt2/2 samples, branching vas-
cular networks were reduced to small clusters of under-
sized vessel lengths or sprouts (Figures 2E, 2F, and 3B).By these analyses, it appeared that the numbers of
nascent EC progenitors (angioblasts) are significantly
reduced and vessel maturation is impaired in Arnt2/2
embryos.
ARNT Is Required for Hematopoiesis in P-Sp
Explants
During embryogenesis, hematopoietic cells (herein re-
ferred to as ‘‘HCs’’) arise within two distinct anatomic
Figure 2. Impaired Vascular Network Formation by Arnt2/2 P-Sp
Explants
P-Sp regions (white dotted lines) from 9.5 dpc Arnt+/+ (A) and Arnt2/2
(B) somite matched embryos were removed and cultured on OP9 stro-
mal cells and immunostained with anti-PECAM (C–F). P-Sp explants
from Arnt+/+ embryos (C and D), but not Arnt2/2 embryos (E and F),
formed extensive PECAM+ vascular beds (white arrowheads) and
networks (black arrowheads). In contrast, representative Arnt2/2 ex-
plants exhibit reduced PECAM staining of tissue outgrowth (E) or
a few random PECAM+ cells ([F], open arrowhead). Wild-type explants
(G and H) observed in phase contrast micrographs generated exten-
sive nonadherent round hematopoietic cells (arrows), which are lack-
ing inArnt2/2P-Sp cultures (I and J). Magnifications: (A) and (B), 1003;
(C), (E), (G), and (I), scale bar 100 mm; (D), (F), and (J) 1003; (H), 2003.
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sac, while definitive hematopoiesis takes place in the
AGM of the embryo proper (Medvinsky and Dzierzak,
1996; Sanchez et al., 1996). We have previously charac-
terized an ARNT-dependent yolk sac hematopoietic
defect (Adelman et al., 1999); therefore, we determined
whether definitive embryonic hematopoiesis was also
compromised in the Arnt2/2 animals. We detected
some HCs (primarily erythrocytes) migrating through
the heart and vessels of 9.5 dpcArnt2/2 embryos. To an-
alyze definitive hematopoiesis further, we employed
P-Sp cultures. We observed relatively few nonadherent
HCs in the Arnt2/2 specimens (Figures 2I and 2J). In di-
rect contrast, Arnt+/+ explants produced numerous
round nonadherent HCs (Figures 2G and 2H). Nonadher-
ent cells were harvested from wild-type and mutant
cultures and assayed for expression of the pan-hemato-
poietic marker CD45 by flow cytometry. CD45+ cells
were consistently detected in Arnt+/+ P-Sp cultures by
day 6, whereas Arnt2/2 P-Sp cultures exhibited less
than 1% of wild-type CD45+ cell numbers over the 14
day culture period (data not shown), indicating a sub-
stantial defect in hematopoietic development.
Because of the dramatically reduced number of non-
adherent cells detected in Arnt2/2 P-Sp cultures, we
further analyzed hematopoietic potential by culturing
the limited number of cells in hematopoietic progenitor
methylcellulose assays. As expected, cells from Arnt+/+
P-Sps produced a variety of colony-forming cells (CFCs)
(primarily granulocyte/macrophage [GM] and erythroid
[E]). In contrast, replated Arnt2/2 nonadherent cells ex-
clusively produced mast cells. These data are consistent
with the Arnt2/2 extraembryonic defect where yolk sac
cells generate fewer hematopoietic colony-forming units
(CFUs) compared to wild-type controls (Adelman et al.,
1999). We concluded that both primitive and definitive
hematopoiesis is significantly impaired in embryos lack-
ing HIF activity.
Arnt2/2 P-Sp Explants Can Be ‘‘Rescued’’ with
Wild-Type Sca-1+ Bone Marrow-Derived Cells
Using P-Sp explant cultures, Takakura et al. (2000) have
previously reported that hematopoietic stem cells
(HSCs) contribute to angiogenic vessel development
by providing angiopoietin-1 (Ang-1) during embryogen-
esis. We therefore asked to what extent does angioblast
production and differentiation require the presence of
HCs? To determine if the vasculo-angiogenic defect ex-
hibited by Arnt2/2 P-Sp explants could be ameliorated
by the addition of wild-type Sca-1+ HCs, Sca-1+ cells
isolated from the bone marrow of wild-type GFP+ mice
were added to the cultures. Remarkably, the addition
of enriched Sca-1+GFP+ HCs completely rescued the
vessel defect in Arnt2/2 explants (Figure 3). The angio-
genic potential of these cultures was analyzed by mea-
suring the lengths of sprouting vessels with an ImageJ
software program (see Experimental Procedures). While
we were unable to measure vessel length of many unre-
scued Arnt2/2 explants due to lack of PECAM staining,
the few explants containing some vascular networks
exhibited a mean vessel length of 0.43 6 0.31 mm (Fig-
ure 3B, asterisk, and Figure 3G, number sign). In con-
trast, the mean vessel length of Arnt+/+ networks was
1.396 0.11 mm. In the rescue experiments, Arnt2/2 cul-tures exhibited vessel lengths (1.36 6 0.31 mm), which
were not significantly different from those detected in
the Arnt+/+ cultures (p < 0.93) (Figure 3G). These results
indicate that the Sca-1+ HCs can rescue the HIF vessel
defect.
It has been reported previously that bone marrow
stem or progenitor cells can contribute to endothelial
cell populations during adult neovascularization (Kocher
et al., 2001; Lyden et al., 2001; Rafii and Lyden, 2003). In
order to determine if the wild-type donor Sca-1+GFP+
cells were the source of endothelial cells observed in
rescue experiments, P-Sp cultures were treated with
DiI-Ac-LDL red fluorescent lipoprotein to label vascular
endothelial cells. An epifluorescence microscope was
used to visualize and then overlay the red and green
fluorescence. Importantly, GFP+ cells failed to contrib-
ute to the EC population, as no overlap between green
fluorescence from the donor GFP+ HCs with red fluores-
cence from the DiI-Ac-LDL+ ECs was observed (Figures
3H and 3I). While HCs retained their green fluorescence
after 14 days of culture, the tracks of endothelial net-
works surrounding the explant remained GFP2 (Figures
3J–3M). Thus, donor Sca-1+ cells did not ‘‘transdifferen-
tiate’’ into ECs, and vascular ECs originated exclusively
from P-Sp explant tissues.
To our surprise, a large number of nonadherent GFP2
cells were also observed in the rescued P-Sp cultures.
Under higher magnification, we noted the presence of
hematopoietic colonies (Figures 3N and 3P) that were
GFP2 under green fluorescence (Figures 3O and 3Q).
To determine if hematopoiesis was promoted by the
addition of wild-type Sca-1+GFP+ HCs to the Arnt2/2
P-Sp explants, HCs from these cultures were analyzed
for CD45 expression and lack of GFP. Nonadherent cells
from individual wild-type and mutant cultures were har-
vested, stained for CD45, and gated CD45+ cells were
evaluated for GFP expression by flow cytometry (Table
1). For example, one P-Sp explant generated from an 18
somite Arnt+/+ embryo produced nonadherent cells that
were 89.3% CD45+, of which 44.4% were GFP2. Simi-
larly, an 18 somite Arnt2/2 embryo produced 88.7%
CD45+ nonadherent cells of which 66.4% were GFP2. In-
deed, the CD45+ population in each of the rescued cul-
tures was composed of both CD45+GFP+ donor-derived
HCs and CD45+GFP2 cells originating from the P-Sp ex-
plant tissue. Again, less than 1% CD45+ cells were de-
tected in unrescued Arnt2/2 explants. As a control, we
demonstrated that the original donor Sca-1+GFP+
bone marrow cells cultured on OP9 stroma for the 14
day period under identical conditions did not lose their
fluorescence. The data confirm that both Arnt+/+ and
Arnt2/2 tissues contribute to the CD45+ hematopoietic
population under these rescue conditions (Table 1).
Therefore, we concluded that bone marrow-derived
HCs contribute important growth factors for both hema-
topoietic and vascular differentiation in P-Sp explants.
VEGF Protein Levels Are Reduced in Arnt2/2
Embryos
As a subunit of HIF, ARNT is critical for the induction of
O2-regulated genes such as Pgk, a glycolytic enzyme,
and Vegf, a critical endothelial growth and survival fac-
tor. It had previously been reported that the vascular de-
fects of Hif-1a2/2 embryos were not due to decreased
HIF Regulates Early Vascular Development
85Figure 3. Wild-Type Sca-1+GFP+ Bone Marrow Cells Rescue Arnt2/2 P-Sp Explants
Sca-1+ cells isolated from the bone marrow of wild-type GFP+ mice were added to P-Sp explant cultures and stained for PECAM after 14 days
(C–F). As a control, representative untreated Arnt+/+ (A) and Arnt2/2 (B) P-Sp cultures are shown. Rescued vascular networks (asterisk) from
Arnt2/2 explants (C–F) were comparable to wild-type controls (A). (G) Measurements of lengths from ten individual vessels extending from
the vascular beds expressed as mean6 SEM distance from five independent wild-type (gray) and mutant (white) rescued explants. As a control
(pound sign), the mean 6 SEM from an untreated Arnt2/2 culture with minimal vessel staining (B) is shown. The horizontal lines represent
average vessel lengths for the Arnt+/+ and Arnt2/2 cultures (p% 0.98). (H) DiI-Ac-LDL uptake of endothelial cells from a rescued P-Sp culture
showing a peripheral ring of cells that includes the vascular networks. (I) Higher magnification showing no overlap between the DiI-Ac-LDL+ ECs
originating from the explant and the GFP+ hematopoietic donor cells in rescued cultures. (J–M) Higher magnification phase contrast (J and L)
and counterpart green fluorescent (K and M) micrographs demonstrating track of ECs (dotted white lines) that do not incorporate GFP+
cells. (N–Q) Higher magnification phase contrast (N and P) and green fluorescent (O and Q) micrographs demonstrating nonadherent hemato-
poietic colonies that are GFP2 arising from the rescued explants. Magnifications: (A)–(F), scale bar 100 mm; (H), 1003; (J)–(K), 4003; (I) and
(L)–(Q), 2003.embryonic Vegf mRNA but rather mesenchymal cell
death (Kotch et al., 1999). Therefore, we analyzed Vegf
mRNA levels in Arnt2/2 embryos. In situ hybridization
performed on sagittal sections of 9.5 dpc Arnt+/+ and
Arnt2/2 samples demonstrated no overall differences
in Pgk and Vegf mRNA abundance with the exception
of cells in the cardiac region (Figures 4Aa–4Ad). Further-
more, mRNA quantification by real-time PCR of HIF tar-
gets Vegf, Ang-1, Epo, bFgf, VE-cadherin, Tie-2, Flk-1,
Flt-1,Aldolase, andPgk from individual somite-matched
whole embryos (9.5 dpc) failed to demonstrate any sta-
tistically significant differences between Arnt+/+ and
Arnt2/2 samples (data not shown). We confirmed that
ARNT2 (a related bHLH-PAS protein) is not expressed
in HCs, making ARNT essential for HIF activity in these
cells (Figures S1A–S1D). Additionally, HIF-1a protein
was detected in Arnt2/2 embryo sections, but nuclear
staining was reduced compared toArnt+/+ samples (Fig-ures S1E–S1H). No significant differences were ob-
served between Arnt+/+ and Arnt2/2 samples by immu-
nostaining for the VEGF receptor Flk-1, Ang-1, or the
Ang-1 receptor Tie-2 (Figure S2). However, VEGF pro-
tein levels were clearly reduced in Arnt2/2 embryonic
sections, especially in the hematopoietic compartment
(Figures 4Ag and 4Ah). We have previously demon-
strated that VEGF is posttranscriptionally regulated by
HIF in subcutaneous tumors (Covello et al., 2005). We
confirmed these observations by measuring VEGF pro-
tein levels in whole-cell or postnuclear lysates obtained
from somite-matched 9.5 dpc embryos by ELISA.Arnt2/2
embryos exhibited a 50% decrease in VEGF protein levels
as compared to Arnt+/+ controls (Figure 4Ai). Therefore,
while Vegf mRNA levels were similar in wild-type and
mutant samples, VEGF protein was reduced in the ab-
sence of ARNT. The significance of these results is ad-
dressed in the discussion.
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of Apoptotic Hematopoietic Cells
As stated above, Hif-1a2/2 embryos exhibit mesenchy-
mal cell death (Kotch et al., 1999). While programmed
cell death is essential for some developmental pro-
cesses, apoptosis is also associated with embryonic pa-
thologies and lethality (Lindsten et al., 2000). Because
HIF reportedly exerts pro- and/or antiapoptotic effects
(Piret et al., 2002, 2005; Sowter et al., 2001), we deter-
mined if Arnt deficiency is associated with changes in
either proliferation or programmed cell death. Trans-
verse and sagittal embryonic sections were subjected
to staining with Ki67 and terminal transferase-mediated
dUTP nick end labeling (TUNEL) to evaluate proliferation
and apoptosis, respectively (Figure 4B). No differences
were noted in Ki67 staining (data not shown). Although
cell death is a natural component of embryogenesis,
we detected a significant increase in the number of
TUNEL+ cells in Arnt2/2 sections from 9.5 dpc embryos
compared to wild-type controls (Figure 4B). Of note, in-
creased TUNEL+ cells were most significant in regions of
the dorsal aorta, HCs, and somitic vessels of theArnt2/2
embryos (Figures 4Bb, 4Bd, and 4Bf). Statistical analy-
sis revealed a significant increase in the number of
TUNEL+ HCs in Arnt2/2 sections compared to Arnt+/+
controls (Figure 4Bg). These results suggest that ARNT
influences the survival but not the proliferation of cells
in 9.5 dpc embryos, especially HCs.
To further evaluate the apoptotic defect in HCs of
Arnt2/2 embryos, we took advantage of explants where
exogenous Ang-1 was added (see below). Under these
culture conditions, hematopoiesis was observed in
seven out of 16 Arnt2/2 explants, indicated by the pres-
ence of CD45+ cells. The recovered nonadherent CD45+
Arnt2/2 cells from these culture conditions were ana-
lyzed for apoptosis by flow cytometry with Annexin V
staining. Annexin V+ cell numbers were increased in
Arnt2/2 explants (mean 6 SE, 19.39% 6 9.77%), com-
pared to wild-type levels (4.26% 6 2.40%) (Table 2). Of
note, CD45+ nonadherent cell numbers in the remaining
nine Arnt2/2 explants were insufficient to analyze, sug-
gesting that Ang-1 alone does not consistently rescue
Table 1. Nonadherent Hematopoietic Cell Numbers from P-Sp








+/+ 23 86.9 55.8
+/+ 18 89.3 44.4
+/2 20 91.0 58.9
+/2 16 90.6 41.0
+/2 15 93.6 61.4
2/2 18 88.7 66.4
2/2 17 90.3 57.3
2/2 16 89.6 47.6
2/2 15 92.1 56.2
2/2 11 90.9 38.3
All P-Sp explants were supplemented with 200–300 Sca-1+GFP+
wild-type bone marrow cells per culture. Nonadherent cells were
harvested, and CD45+ cells were gated and further analyzed for
GFP expression. Numbers are denoted as percents. Negative
control, unrescued Arnt2/2 explants did not generate CD45+ cells.
Positive control, isolated bone marrow cells remained GFP+ over
the course of the 14 day experiment.the hematopoietic Arnt2/2 defect. The increased An-
nexin V staining exhibited by cells that can be recovered
from Arnt2/2 explants indicate that decreased survival
likely accounts for the severely reduced numbers of
HCs in Arnt2/2 cultures. Thus, it appears that vessel
defects inArnt2/2 embryos are influenced by decreased
VEGF levels, and HCs are a likely paracrine VEGF
source. Moreover, reduced VEGF levels also contribute
to the intraembryonic hematopoietic defect in Arnt2/2
embryos.
VEGF Is Sufficient to Rescue the Arnt2/2 P-Sp Defect
The dramatic reduction in VEGF expression may be re-
sponsible for vascular defects noted in Arnt2/2 em-
bryos. Because VEGF is an important survival factor
for multiple cell types, VEGF would also be indirectly
necessary for normal vessel formation and development
by promoting HC viability. Furthermore, since VEGF is
expressed in HCs, we hypothesized that VEGF could
rescue the Arnt2/2 vascular phenotype. To determine
if exogenous VEGF could overcome the Arnt2/2 hema-
topoietic and vascular defects, VEGF 164 isoform was
added to the P-Sp cultures (Figures 5Aa–5Ad). Vessel
lengths observed in the vascular networks were en-
hanced in VEGF-treated cultures and became indistin-
guishable between Arnt+/+ and Arnt2/2 explants (Fig-
ures 5Aa–5Ad and 5B). To confirm the significance of
VEGF for endothelial development in P-Sp explants,
we analyzed the effect of blocking VEGF signaling by
supplementing the cultures with recombinant soluble
Flt-1-Fc receptor. The development of vascular beds
and networks was significantly inhibited in both Arnt+/+
and Arnt2/2 P-Sp cultures (Figures 5Ai–5Al). While Flt-
1-Fc did not reduce HC numbers after 14 days of culture,
Flt-1-Fc treatment resulted in reduced numbers of PE-
CAM+ cells (Figures 5Ai–5Al). VEGF rescued Arnt2/2
P-Sp cultures also contained abundant numbers of non-
adherent CD45+ hematopoietic cells, similar to Arnt+/+
controls (data not shown). We next examined hemato-
poietic potential in the VEGF-treated P-Sp cultures
(Table S2) and found that although reduced, Arnt2/2
P-Sp cultures generated CFCs more efficiently than un-
treated cultures. These data indicate that paracrine
VEGF promotes both hematopoietic expansion and ves-
sel development in Arnt2/2 P-Sp cultures.
Since HSCs are also an important source of Ang-1
(Takakura et al., 2000), we determined if the Arnt2/2
P-Sp explants could be rescued with exogenous Ang-1
(Figures 5Ae–5Ah). The vascular bed size in Arnt+/+ and
Arnt2/2 explants was greatly increased by the addition
of Ang-1 alone (Figures 5Ae–5Ah and 5B) or in combina-
tion with VEGF (Figure S3). In both conditions, a large
mantle of cells adjacent to the original explants was
PECAM+, suggesting that Ang-1 enhanced the prolifera-
tion of ECs. Treatment with both Ang-1 and VEGF in-
creased vessel lengths in Arnt2/2 networks (Figure S3,
asterisks), compared to VEGF treatment alone (Figures
5Ae–5Ah, asterisks). In contrast, vessel lengths re-
mained small in networks within cultures treated with
Ang-1 alone where staining demonstrated EC conges-
tion (Arnt+/+: 0.755 6 0.136 mm, and Arnt2/2: 0.597 6
0.045 mm, p < 0.397) and a decrease in the fine pattern-
ing of branches (Arnt+/+: 1.1596 0.090 mm, andArnt2/2:
1.248 6 0.010 mm, p < 0.224) (Figure 5Ag–5Ah and 5B).
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87Figure 4. Reduced VEGF Levels in Arnt2/2
Embryos Result in Increased Hematopoietic
Cell Death
(A) VEGF protein levels are reduced inArnt2/2
9.5 dpc embryos. Transverse sections of
Arnt+/+ (Aa–Ac) and Arnt2/2 (Ad–Af) embryos
probed for Vegf (Ab and Ae) and Pgk (Ac and
Af) showing no overall differences in expres-
sion. As a comparison, hematoxylin-stained
Arnt+/+ (Aa) and Arnt2/2 (Ad) serial sections
are shown. VEGF immunohistochemistry of
transverse sections of 9.5 dpc (28 somites)
Arnt+/+ (Ag) and Arnt2/2 (Ah) embryos show-
ing reduced protein expression in the mutant
embryo. Expression is particularly reduced in
the hematopoietic compartment (higher
magnification inlay) of the Arnt2/2 embryo
(arrow). Dorsal aorta, da; hematopoietic cells,
HCS; heart, ht; neural tube, nt. (Ai) VEGF
levels from whole-cell or postnuclear lysates
of individual 9.5 dpc (21 somites) Arnt+/+
(black) and Arnt2/2 (white) embryos analyzed
by ELISA. Error bars indicate standard error
of the mean (n = 3; *p < 0.005).
(B) Increased apoptosis in Arnt2/2 embryos.
TUNEL immunostaining (FITC, green) of
transverse sections counterstained with he-
matoxylin (Ba and Bb) or nuclear DAPI (blue)
(Bc and Bd) and hematoxylin-stained sagittal
sections (Be and Bf) of Arnt+/+ (Ba, Bc, and
Be) and Arnt2/2 (Bb, Bd, and Bf) embryos.
An increase in TUNEL+ HCs was detected
in the dorsal aorta ([Bd], arrowheads) of
Arnt2/2 transverse sections compared to the
modest TUNEL staining observed in the
Arnt+/+ control (Bc). Increased numbers of
TUNEL+ cells in the dorsal aorta ([Bf], arrows)
and intrasomitic ([Bf], dotted lines) regions
are observed in Arnt2/2 sagittal sections.
Comparison of apoptotic cells in the dorsal
aortic region of Arnt+/+ (black) and Arnt2/2
(white) transverse sections (Bg). Numbers of
apoptotic cells are expressed as total num-
bers of FITC+ cells; *p < 0.005. Magnifications:
(Aa)–(Af), (Ba), (Bb), (Be), and (Bf), 503; (Ag)–
(Ah), (Bc), and (Bd), 1003 (inserts 4003).It should be noted that only 37% of Arnt2/2 explants
demonstrated significant vessel differentiation upon ex-
ogenous Ang-1 addition. Moreover, hematopoiesis was
Table 2. Percent of Apoptotic CD45+ Cells Obtained from P-Sp
Explants
Arnt+/+ Arnt2/2
%CD45+ (%AnnV+) %CD45+ (%AnnV+)
51.3 2.3 19.7 35.8
93.3 1.18 19.4 24.1
12.6 6.03 14 17.2
54.1 4.02 10.8 9.05
52.83a 3.38a 15.97a 21.54a
28.54b 1.83b 3.75b 9.80b
Nonadherent cells from four independentArnt+/+ and Arnt2/2 day 14
P-Sp cultures treated with 300 ng/ml Ang-1 were analyzed by flow
cytometry. Gated CD45+ cells were analyzed for numbers of apopto-
tic cells that stained for Annexin V and were expressed as percent-
ages.
a Mean, of all samples above.
b Standard deviation, of all samples above; p < 0.005.rescued in only one half of the Arnt2/2 explants supple-
mented with Ang-1. We concluded that Ang-1 is not
sufficient to fully rescue the Arnt2/2 P-Sp vascular de-
fect. In direct contrast, exogenous VEGF rescues vascu-
logenesis, angiogenesis, and hematopoiesis in mutant
explants.
Discussion
In this study, we determined that HIF is essential for vas-
culogenesis, angiogenesis, and hematopoiesis in the
P-Sp/AGM. We employed a P-Sp ex vivo approach to
analyze HIF’s involvement in embryonic vessel develop-
ment withArnt2/2 embryos to abrogate all HIF transcrip-
tional activity (Table S3). The explant assay allows us to
evaluate vasculogenesis, angiogenesis, and hemato-
poiesis in the intraembryonic P-Sp region without the
complication of other cardiovascular defects. The addi-
tion of wild-type Sca-1+ HCs promoted both endothelial
and hematopoietic differentiation of Arnt2/2 explants.
VEGF, whose protein levels are dramatically reduced
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(A) Treatment of P-Sp explants with VEGF or Ang-1 promotes vessel growth. Addition of 100 ng/ml VEGF to Arnt2/2 cultures (Ac and Ad) pro-
motes fine patterning and branching in the vascular networks (asterisk).Arnt+/+ cultures (Aa and Ab) are shown as controls. Addition of 300 ng/ml
Ang-1 does not result in proper angiogenesis but promotes congestion (^) in the vascular networks in Arnt2/2 cultures (Ag and Ah) as well as the
Arnt+/+ P-Sps ([Ae and Af], p < 0.722). However, the congestion was worse in the Arnt2/2 explants. Addition of 300 ng/ml of Flt-1-Fc (Aj–Al)
inhibited proper vessel development as compared to control (Ai) P-Sp explants. All explants were stained for PECAM. Magnifications: scale
bars 100 mm.
(B) Measurement of vessel areas from VEGF- or Ang-1-treated P-Sp explants. Ten sprouting vessel measurements from five independent
Arnt2/2 and Arnt+/+ P-Sp explants were analyzed. Results are shown as mean vessel lengths (6SEM) for wild-type (black) and mutant (white)
VEGF-treated or Ang-1-treated explants. Note that Ang-1 promoted vessel congestion.
(C) Proper vessel development requires HIF-dependent factors supplied by hematopoietic cells. Differentiation of hematopoietic cells and vas-
culature is HIF dependent during three separate events. (1) HIF promotes the survival of hematopoietic cells. (2) Hematopoietic cells serve as
a paracrine source of VEGF, which induces vasculogenesis by increasing the production and proliferation of endothelial cells. (3) Hematopoietic
cells are also a source of Ang-1, promoting angiogenesis, as measured by the remodeling and maturation of vessels (Takakura et al., 2000). Loss
of Arnt results in HIF deficiency, increased numbers of apoptotic cells in the hematopoietic compartment, and a reduction of VEGF production.in Arnt2/2 embryos, fully rescued the P-Sp explant de-
fects when added to the cultures. Reduced VEGF levels
may be the cause of increased numbers of apototic
TUNEL+ or Annexin V+ HCs observed in Arnt2/2 embry-onic histological sections or P-Sp explants. The de-
creased survival of and VEGF production by HCs in
Arnt2/2 embryos likely contribute to paracrine defects
preceding abnormal vessel development, as shown in
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89Figure 5C. Therefore, O2 sensing by HIF is critical for in-
traembryonic blood and vessel development, in part by
promoting the production of VEGF.
Our findings support the hypothesis that growth fac-
tors supplied in a paracrine fashion by HCs are important
for vessel development. AML12/2 embryos have previ-
ously been shown to exhibit both hematopoietic and
angiogenic defects (Takakura et al., 2000). The AML1
(Runx1)-CBFb transcription factor is required for the
generation of hematopoietic progenitors, and AML12/2
embryos die by 12.5 dpc. In similar P-Sp experiments,
addition of HCs or exogenous Ang-1 rescued the AML1
angiogenic defect. In contrast, we show that Ang-1
only partially rescued theArnt2/2 vessel and hematopoi-
etic defects. While theAML12/2 embryos survive to 11.5
dpc with intact large vessels, HIF deficiency results in
more severe vascular defects whereby Arnt2/2 embryos
are developmentally delayed with poor vessel develop-
ment by 9.5 dpc. Therefore, we show that HCs are also
required for earlier vascular differentiation by secreting
VEGF, a growth factor important for angioblast specifi-
cation and vasculogenesis (Weinstein, 1999). Because
some PECAM+ vessels are observed in 9.5 dpc Arnt2/2
embryos, sufficient levels of VEGF may be available for
mesoderm differentiation into a limited number of he-
mangioblasts, hematopoietic precursors, and/or angio-
blasts. However, hypoxic induction of VEGF is required
for extensive proliferation, survival, differentiation, matu-
ration, and/or migration of these cells (Figure 5C). While
circulating bone marrow-derived endothelial progenitor
cells (EPCs) contribute to adult ‘‘neovasculogenesis’’
(Ingram et al., 2005), HCs do not contribute to vessels
generated in the P-Sp explants. Therefore, the relation-
ship between hematopoietic and endothelial cells during
embryonic development and in adults remains a compli-
cated, context-dependent process.
Hypoxia and ischemia trigger multiple responses to
overcome decreased O2 availability, including the ex-
pression of growth factors required for establishment
of a functional circulatory system. While unable to de-
tect a significant difference in Vegf transcript levels be-
tween Arnt2/2 and Arnt+/+ 9.5 dpc embryos, we clearly
observed decreased VEGF protein levels in mutant sam-
ples. The transcription of Vegf, which contains hypoxic
response elements (HREs) in 50 and 30 flanking regions
of the gene, is strongly induced by HIF in response to
low O2 tension (Forsythe et al., 1996; Semenza, 1999).
However, VEGF regulation by hypoxia also includes in-
creased mRNA translational efficiency, protein stability,
and biological activity (Chan et al., 2002; Claffey et al.,
1998; Stein et al., 1998).
Decreased VEGF levels in HCs of 9.5 dpc Arnt2/2 em-
bryos may be linked to their increased rate of apoptosis.
VEGF is a known survival factor for various cell types, in-
cluding HSCs via a cell-autonomous autocrine pathway
(Brusselmans et al., 2005; Gerber et al., 2002). Embry-
onic inactivation of Vegf, or its receptor Flk-1, results
in decreased numbers of blood islands, endothelial
cells, and major vessels (reviewed in Carmeliet and Col-
len [2000]). A requirement for VEGF in P-Sp explant out-
growth has also been demonstrated by the partial res-
cue of similar hematopoietic and vascular defects in
explants from mice lacking CREB binding protein (Oike
et al., 1999). We show that inhibition of VEGF signalingusing a soluble Flt-1-Fc receptor blocks EC develop-
ment in P-Sp explant assays, supporting previous
work using an anti-Flk-1 antibody (Takakura et al.,
1998). While some evidence suggests Ang-1 is a hema-
topoietic mitogenic or survival factor (Arai et al., 2005;
Kopp et al., 2005), we determined that Ang-1 is insuffi-
cient to rescue the Arnt2/2 P-Sp explants. In contrast
to VEGF, Ang-1 protein levels were not reduced in
Arnt2/2 embryos. Moreover, Ang-12/2 embryos exhibit
normal vascular differentiation prior to day 11.5 dpc
(Suri et al., 1996), suggesting that the requirement for
VEGF precedes Ang-1. Taken together, VEGF appears
to be critical for the survival and subsequent maturation
of early hematopoietic and endothelial cells. Further-
more, hypoxia in the early embryo controls VEGF levels
during these events.
Recent studies have examined the role of HIF in ECs
with a conditional Hif-1a2/2 allele (Tang et al., 2004). Al-
though mice in which Hif-1a is deleted in the endothelial
and hematopoietic compartments after day 9.5 dpc are
viable, angiogenesis in adult mice is compromised in
these animals. In vitro, Hif-1a2/2 ECs exhibit migration,
proliferation, and survival defects. While these studies
contribute to our understanding of hypoxic responses
in EC biology, they may not be as informative about em-
bryonic vascularization because immortalized adult EC
lines were used. Furthermore, hypoxic responses in
Hif-1a2/2 ECs are not completely abrogated as they
maintain HIF-2a expression, making the analysis of
Arnt2/2 embryos important for determining the role of
HIF in vessel development. Future work will thoroughly
evaluate the role of ARNT in EC behavior.
Our data indicate that HIF regulates cardiovascular
development. In particular, it is required for the genera-
tion of both the hematopoietic and vascular organ sys-
tems. Although the requirement for HIF in these pro-
cesses has been established, the molecular nature of
all the relevant signals involved in embryonic develop-
ment remains unclear. We show that HCs are required
for proper vessel emergence and development. Further-
more, we presently suggest that HIF is important for cell
survival during embryogenesis through mechanisms




All animal experiments were conducted in accordance with NIH
guidelines. Generation of Arnt+/2 mice used in these experiments
has been previously described (Maltepe et al., 1997). 9.5 dpc em-
bryos were harvested and staged by counting somites. P-Sp ex-
plants were cultured at 37ºC in humidified 5% CO2 on OP9 stromal
cell layers as previously described (Takakura et al., 2000). Briefly,
RPMI 1640 (GIBCO-BRL, Gaithersburg, MD) culture medium con-
tained 10% FCS (Hyclone), 1025 M 2ME (Sigma, St Louis, MO), 50
ng/ml stem cell factor (SCF), 20 ng/ml interleukin-6 (IL-6), and 2 U/
ml erythropoietin (EPO). For the rescue or inhibition experiments,
300 ng/ml of recombinant Flt-1-Fc chimera protein, 100 ng/ml
VEGF, and/or 300 ng/ml Ang-1 were added. All growth factors
were purchased from R&D Systems. Sca-1+ HCs from the bone mar-
row of GFP+ mice (Okabe et al., 1997) were selected with magnetic
beads as described (Stem Cell Technologies, Vancouver, Canada),
and 200–300 Sca-1+ cells were added to each well. After 14 days,
cultures were stained for PECAM (see below). Hematopoietic cells
were harvested and analyzed at different time points for CD45
or Annexin V expression (see below).
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After PECAM staining, photomicrographs of P-Sps were integrated
with a LEICA DC 500 camera and program. Angiogenic vessel
lengths were measured by ImageJ analysis. Ten individual measure-
ments of five separate Arnt+/+ and Arnt2/2 explants were used to
determine average vessel lengths and standard deviations of the
mean. p values were calculated by two-tailed Student’s t test.
Methylcellulose Colony Assays
The in vitro colony assays for hematopoietic progenitors were per-
formed as recommended for M3434 media (Stem Cell Technologies)
with the addition of 23 103 nonadherent cells harvested from day 12
P-Sp explants. Cultures were performed in triplicate and colonies
were enumerated at day 7.
Cell Preparation and Flow Cytometry
Nonadherent hematopoietic cells were harvested from P-Sp cultures
at the days indicated. Cells were incubated in 1:100 FCgIII/II receptor
(Pharmingen, San Jose, CA) blocking buffer for 20 min at 4ºC. After
washing, cells were incubated with PE-conjugated CD45 or APC-
conjugated Annexin V (Caltag, Buckingham, UK) at 1:100 for 20 min
at 4ºC, washed, and visualized by FACS Vantage (Becton and Dick-
inson, San Jose, CA). Results were analyzed by Flo-Jo (Tree Star).
Immunohistochemistry
PECAM antibody (MEC13.3, Pharmingen) was used for whole-mount
staining as described (Oike et al., 1999). Tissue sections were incu-
bated with anti-CD34, anti-Flk1, anti-Tie2 (Pharmingen), anti-Ang-1
(Abcam), or anti-VEGF (NeoMarkers, Fremont, CA) and developed
with HRP-conjugated secondary antibodies followed by treatment
with diaminobenzidine (DAB, Vector Laboratories, Burlingame,
CA). A BioVision (Mountain View, CA) Apo-BrdU-FITC In Situ DNA
fragment kit was used to assay apoptosis in embryonic tissues. Ap-
optotic measurements were made by capturing sequential images of
FITC (BrdU staining) and DAPI (nuclear staining) channels of identical
tissue sections with an epiflourescent microscope. Images were
overlayed in Photoshop and quantified, and results were expressed
as numbers of apoptotic cells within dorsal aortic regions.
RNA In Situ Hybridization
9.5 dpc embryos from Arnt+/2matings were fixed in 4% paraformal-
dehyde for 48 hr. Genotypes were analyzed from yolk sac DNA by
PCR. Subsequent tissue embedding, sectioning, and in situ hybrid-
ization were performed as previously described (Jain et al., 1998).
Sense and antisense RNA probes were generated with T7 and Sp6
RNA polymerases and [35S]thio-UTP. Pgk and Vegf probes were
generated by reverse-transcription PCR with the following primers:
Pgk, 50 50-CTTGGACTGTGGTACTGAGAG and 30 50-CTGAATCTTGC
GCTAACACCA; and Vegf, 50 50-CCATGCAGATCATGCGGATC and 30
50-CAAAGTTCTCCTCGAAGGATC. Hybridization to sense probes
revealed only low levels of general background staining (data not
shown).
RNA and Protein Quantification
Real-time detection PCR (RTD-PCR) was performed as previously
described (Ramirez-Bergeron et al., 2004). A VEGF ELISA kit was
used to measure VEGF protein levels from individual whole-embryo
cell extracts (Biosource, Camarillo, CA). Briefly, stage-matched em-
bryos were harvested and lysed. Protein concentrations of whole
cell or postnuclear extracts were quantified and analyzed as sug-
gested by the manufacturer.
Supplemental Data
Supplemental Data include immunostaining of 9.5 dpc Arnt+/+ and
Arnt2/2embryos for ARNT2, HIF-1a, Ang-1, Flk-1, and Tie-2 proteins.
We also show rescue of Arnt2/2 P-Sps with a combination of Ang-1
and VEGF. Finally, three tables providing additional information on
embryo genotyping and P-Sp explant results are available at http://
www.developmentalcell.com/cgi/content/full/11/1/81/DC1/.
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